Dual Blockade of Inhibitory Immunoreceptors TIGIT and PD-1 Produces Optimal Synergistic Anti-Tumor Effects
Keywords:Immunology, TIGIT, PD-1, checkpoint inhibitors, tumor, cancer
Recent investigation into immunoregulatory roles of both TIGIT and PD-1 T cell receptors reveals that their suppressive effects converge with the inhibition of another T cell receptor, CD226. Co-blockade of these receptors reduced tumor volume in vivo and shows potential as a promising new cancer immunotherapy.
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
© The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International license.